Comparative pathogenesis and systems biology for biodefense virus vaccine development

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Bowick, Gavin C ^a   Barrett, Alan D T ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE RECEPTOR CCR5; CHIMERIC ANTIBODY; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLASMID DNA; RANTES; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE; YELLOW FEVER VACCINE; VACCINE;

BIODEFENSE VIRUS VACCINE DEVELOPMENT; BIOINFORMATICS; BIOLOGICAL WARFARE; BIOSAFETY; COMPARATIVE STUDY; DENGUE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; EBOLA HEMORRHAGIC FEVER; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; JUNIN VIRUS; MARBURG HEMORRHAGIC FEVER; MICROARRAY ANALYSIS; NONHUMAN; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RIFT VALLEY FEVER; SAFETY; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SMALLPOX VIRUS; SUPPORT VECTOR MACHINE; SYSTEMS BIOLOGY; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALITIS; VESICULAR STOMATITIS VIRUS; VIRUS STRAIN; EPIDEMIC; PATHOGENICITY; RNA VIRUS; RNA VIRUS INFECTION; SMALLPOX;

BIOTERRORISM; DISEASE OUTBREAKS; HOST-PATHOGEN INTERACTIONS; HUMANS; RNA VIRUS INFECTIONS; RNA VIRUSES; SMALLPOX; SYSTEMS BIOLOGY; VACCINES; VARIOLA VIRUS;

EID: 77954557662     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/236528     Document Type: Review

References (75)

1. Carrion R. Jr., Patterson J. L., Johnson C., A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity Vaccine 2007 25 20 4093 4102
2. Lukashevich I. S., Patterson J., Carrion R., A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses Journal of Virology 2005 79 22 13934 13942
3. Bredenbeek P. J., Molenkamp R., Spaan W. J. M., A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins Virology 2006 345 2 299 304
4. Fisher-Hoch S. P., Hutwagner L., Brown B., McCormick J. B., Effective vaccine for lassa fever Journal of Virology 2000 74 15 6777 6783
5. Geisbert T. W., Jones S., Fritz E. A., Development of a new vaccine for the prevention of Lassa fever PLoS Medicine 2005 2 6, article e183
6. Fisher-Hoch S. P., McCormick J. B., Auperin D., Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene Proceedings of the National Academy of Sciences of the United States of America 1989 86 1 317 321
7. Bharadwaj M., Lyons C. R., Wortman I. A., Hjelle B., Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice Vaccine 1999 17 22 2836 2843
8. Bharadwaj M., Mirowsky K., Ye C., Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus) Journal of General Virology 2002 83 7 1745 1751
9. Tuffs A., Experimental vaccine may have saved Hamburg scientist from Ebola fever British Medical Journal 2009 338, article b1223
10. Maiztegui J. I., McKee K. T. Jr., Oro J. G. B., Protective efficacy of a live attenuated vaccine against argentine hemorrhagic fever Journal of Infectious Diseases 1998 177 2 277 283
11. Bambini S., Rappuoli R., The use of genomics in microbial vaccine development Drug Discovery Today 2009 14 5-6 252 260
12. Rappuoli R., Covacci A., Reverse vaccinology and genomics Science 2003 302 5645 602
13. Sevilla N., McGavern D. B., Teng C., Kunz S., Oldstone M. B. A., Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion Journal of Clinical Investigation 2004 113 5 737 745
14. Fritz E. A., Geisbert J. B., Geisbert T. W., Hensley L. E., Reed D. S., Cellular immune response to marburg virus infection in cynomolgus macaques Viral Immunology 2008 21 3 355 363
15. Djavani M. M., Crasta O. R., Zapata J. C., Early blood profiles of virus infection in a monkey model for Lassa fever Journal of Virology 2007 81 15 7960 7973
16. Djavani M., Crasta O. R., Zhang Y., Gene expression in primate liver during viral hemorrhagic fever Virology Journal 2009 6 20
17. Hartman A. L., Ling L., Nichol S. T., Hibberd M. L., Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein Journal of Virology 2008 82 11 5348 5358
18. Hartman A. L., Bird B. H., Towner J. S., Antoniadou Z.-A., Zaki S. R., Nichol S. T., Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus Journal of Virology 2008 82 6 2699 2704
19. Powell P. P., Dixon L. K., Parkhouse R. M. E., An I B homolog encoded by African swine fever virus provides a novel mechanism for downregulation of proinflammatory cytokine responses in host macrophages Journal of Virology 1996 70 12 8527 8533
20. Neilan J. G., Lu Z., Kutish G. F., Zsak L., Lewis T. L., Rock D. L., A conserved African swine fever virus I B homolog, 5EL, is nonessential for growth in vitro and virulence in domestic swine Virology 1997 235 2 377 385 (Pubitemid 27394351)
21. Afonso C. L., Piccone M. E., Zaffuto K. M., African swine fever virus multigene family 360 and 530 genes affect host interferon response Journal of Virology 2004 78 4 1858 1864
22. Zsak L., Lu Z., Burrage T. G., African swine fever virus multigene family 360 and 530 genes are novel macrophage host range determinants Journal of Virology 2001 75 7 3066 3076
23. Ciancanelli M. J., Volchkova V. A., Shaw M. L., Volchkov V. E., Basler C. F., Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism Journal of Virology 2009 83 16 7828 7841
24. Haverty P. M., Frith M. C., Weng Z., CARRIE web service: automated transcriptional regulatory network inference and interactive analysis Nucleic Acids Research 2004 32 W213 W216
25. Haverty P. M., Hansen U., Weng Z., Computational inference of transcriptional regulatory networks from expression profiling and transcription factor binding site identification Nucleic Acids Research 2004 32 1 179 188
26. Vela E. M., Bowick G. C., Herzog N. K., Aronson J. F., Genistein treatment of cells inhibits arenavirus infection Antiviral Research 2008 77 2 153 156
27. Vela E. M., Bowick G. C., Herzog N. K., Aronson J. F., Exploring kinase inhibitors as therapies for human arenavirus infections Future Virology 2008 3 3 243 251
28. Kolokoltsov A. A., Saeed M. F., Freiberg A. N., Holbrook M. R., Davey R. A., Identification of novel cellular targets for therapeutic intervention against ebola virus infection by siRNA screening Drug Development Research 2009 70 4 255 265
29. Querec T. D., Akondy R. S., Lee E. K., Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans Nature Immunology 2009 10 1 116 125
30. Wang Z. W., Sarmento L., Wang Y., Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system Journal of Virology 2005 79 19 12554 12565
31. Jahrling P. B., Hesse R. A., Rhoderick J. B., Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs Infection and Immunity 1981 32 2 872 880
32. Aronson J. F., Herzog N. K., Jerrells T. R., Pathological and virological features of arenavirus disease in guinea pigs: comparison of two Pichinde virus strains American Journal of Pathology 1994 145 1 228 235
33. Bowick G. C., Fennewald S. M., Elsom B. L., Differential signaling networks induced by mild and lethal hemorrhagic fever virus infections Journal of Virology 2006 80 20 10248 10252
34. Bowick G. C., Fennewald S. M., Scott E. P., Identification of differentially activated cell-signaling networks associated with Pichinde virus pathogenesis by using systems kinomics Journal of Virology 2007 81 4 1923 1933
35. Bowick G. C., Spratt H. M., Hogg A. E., Analysis of the differential host cell nuclear proteome induced by attenuated and virulent hemorrhagic arenavirus infection Journal of Virology 2009 83 2 687 700
36. Bowick G. C., Fennewald S. M., Zhang L., Attenuated and lethal variants of pichinde virus induce differential patterns of NF- B activation suggesting a potential target for novel therapeutics Viral Immunology 2009 22 6 457 462
37. Lan S., McLay L., Aronson J., Ly H., Liang Y., Genome comparison of virulent and avirulent strains of the Pichinde arenavirus Archives of Virology 2008 153 7 1241 1250
38. Martinez-Sobrido L., Zuniga E. I., Rosario D., Garcia-Sastre A., de la Torre J. C., Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavires lymphocytic choriomeningitis virus Journal of Virology 2006 80 18 9192 9199
39. Martinez-Sobrido L., Giannakas P., Cubitt B., Garcia-Sastre A., de la Torre J. C., Differential inhibition of type I interferon induction by arenavirus nucleoproteins Journal of Virology 2007 81 22 12696 12703
40. Lan S., Schelde L. M., Wang J., Kumar N., Ly H., Liang Y., Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers Journal of Virology 2009 83 13 6357 6362
41. Lukashevich I. S., Maryankova R., Vladyko A. S., Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF- gene expression Journal of Medical Virology 1999 59 4 552 560
42. Pannetier D., Faure C., Georges-Courbot M.-C., Deubel V., Baize S., Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection Journal of Virology 2004 78 19 10516 10524
43. Baize S., Kaplon J., Faure C., Pannetier D., Georges-Courbot M.-C., Deubel V., Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells Journal of Immunology 2004 172 5 2861 2869
44. Mahanty S., Bausch D. G., Thomas R. L., Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever Journal of Infectious Diseases 2001 183 12 1713 1721
45. Rockx B., Baas T., Zornetzer G. A., Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection Journal of Virology 2009 83 14 7062 7074
46. Muller R., Saluzzo J.-F., Lopez N., Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment American Journal of Tropical Medicine and Hygiene 1995 53 4 405 411
47. Billecocq A., Spiegel M., Vialat P., NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription Journal of Virology 2004 78 18 9798 9806
48. Bouloy M., Janzen C., Vialat P., Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs Journal of Virology 2001 75 3 1371 1377
49. Vialat P., Billecocq A., Kohl A., Bouloy M., The S segment of Rift Valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice Journal of Virology 2000 74 3 1538 1543
50. Schadt E. E., Molecular networks as sensors and drivers of common human diseases Nature 2009 461 7261 218 223
51. Shannon P., Markiel A., Ozier O., Cytoscape: a software environment for integrated models of biomolecular interaction networks Genome Research 2003 13 11 2498 2504
52. Killcoyne S., Carter G. W., Smith J., Boyle J., Cytoscape: a community-based framework for network modeling Methods in Molecular Biology 2009 563 219 239
53. Calvano S. E., Xiao W., Richards D. R., A network-based analysis of systemic inflammation in humans Nature 2005 437 7061 1032 1037
54. Fossum E., Friedel C. C., Rajagopala S. V., Evolutionarily conserved herpesviral protein interaction networks PLoS Pathogens 2009 5 9
55. Uetz P., Dong Y.-A., Zeretzke C., Herpesviral protein networks and their interaction with the human proteome Science 2006 311 5758 239 242
56. Calderwood M. A., Venkatesan K., Xing L., Epstein-Barr virus and virus human protein interaction maps Proceedings of the National Academy of Sciences of the United States of America 2007 104 18 7606 7611
57. Dohkan S., Koike A., Takagi T., Improving the performance of an SVM-based method for predicting protein-protein interactions In Silico Biology 2006 6 6 515 529
58. Koike A., Takagi T., Prediction of protein-protein interaction sites using support vector machines Protein Engineering, Design and Selection 2004 17 2 165 173
59. Shen J., Zhang J., Luo X., Predicting protein-protein interactions based only on sequences information Proceedings of the National Academy of Sciences of the United States of America 2007 104 11 4337 4341
60. Coleman J. R., Papamichail D., Skiena S., Futcher B., Wimmer E., Mueller S., Virus attenuation by genome-scale changes in codon pair bias Science 2008 320 5884 1784 1787
61. Brower-Sinning R., Carter D. M., Crevar C. J., Ghedin E., Ross T. M., Benos P. V., The role of RNA folding free energy in the evolution of the polymerase genes of the influenza A virus Genome Biology 2009 10 2, article R18
62. Cann A. J., Stanway G., Hughes P. J., Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine Nucleic Acids Research 1984 12 20 7787 7792
63. Bae H.-G., Domingo C., Tenorio A., Immune response during adverse events after 17D-derived yellow fever vaccination in Europe Journal of Infectious Diseases 2008 197 11 1577 1584
64. Domingo C., Niedrig M., Safety of 17D derived yellow fever vaccines Expert Opinion on Drug Safety 2009 8 2 211 221
65. Barrett A. D., Teuwen D. E., Yellow fever vaccinehow does it work and why do rare cases of serious adverse events take place? Current Opinion in Immunology 2009 21 3 308 313
66. Pulendran B., Miller J., Querec T. D., Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes Journal of Infectious Diseases 2008 198 4 500 507
67. Poland G. A., Ovsyannikova I. G., Jacobson R. M., Personalized vaccines: the emerging field of vaccinomics Expert Opinion on Biological Therapy 2008 8 11 1659 1667
68. Poland G. A., Ovsyannikova I. G., Jacobson R. M., Application of pharmacogenomics to vaccines Pharmacogenomics 2009 10 5 837 852
69. Gaucher D., Therrien R., Kettaf N., Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses Journal of Experimental Medicine 2008 205 13 3119 3131
70. Thomas P. G., Doherty P. C., Rules to prime by Nature Immunology 2009 10 1 14 16
71. Mosca F., Tritto E., Muzzi A., Molecular and cellular signatures of human vaccine adjuvants Proceedings of the National Academy of Sciences of the United States of America 2008 105 30 10501 10506
72. Tritto E., Muzzi A., Pesce I., The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature Journal of Immunology 2007 179 8 5346 5357
73. Demento S. L., Eisenbarth S. C., Foellmer H. G., Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy Vaccine 2009 27 23 3013 3021
74. Bui H.-H., Botten J., Fusseder N., Protein sequence database for pathogenic arenaviruses Immunome Research 2007 3 1
75. Murphy F. A., Emerging zoonoses: the challenge for public health and biodefense Preventive Veterinary Medicine 2008 86 3-4 216 223